1
|
Hernández-García M, Molina-Barceló A, Vanaclocha-Espi M, Zurriaga Ó, Pérez-Gómez B, Aragonés N, Amiano P, Altzibar JM, Castaño-Vinyals G, Sala M, Ederra M, Martín V, Gómez-Acebo I, Vidal C, Tardón A, Marcos-Gragera R, Pollán M, Kogevinas M, Salas D. Differences in breast cancer-risk factors between screen-detected and non-screen-detected cases (MCC-Spain study). Cancer Causes Control 2021; 33:125-136. [PMID: 34817770 PMCID: PMC8739309 DOI: 10.1007/s10552-021-01511-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Accepted: 10/15/2021] [Indexed: 12/14/2022]
Abstract
Purpose The variation in breast cancer (BC)-risk factor associations between screen-detected (SD) and non-screen-detected (NSD) tumors has been poorly studied, despite the interest of this aspect in risk assessment and prevention. This study analyzes the differences in breast cancer-risk factor associations according to detection method and tumor phenotype in Spanish women aged between 50 and 69. Methods We examined 900 BC cases and 896 controls aged between 50 and 69, recruited in the multicase–control MCC-Spain study. With regard to the cases, 460 were detected by screening mammography, whereas 144 were diagnosed by other means. By tumor phenotype, 591 were HR+, 153 were HER2+, and 58 were TN. Lifestyle, reproductive factors, family history of BC, and tumor characteristics were analyzed. Logistic regression models were used to compare cases vs. controls and SD vs. NSD cases. Multinomial regression models (controls used as a reference) were adjusted for case analysis according to phenotype and detection method. Results TN was associated with a lower risk of SD BC (OR 0.30 IC 0.10–0.89), as were intermediate (OR 0.18 IC 0.07–0.44) and advanced stages at diagnosis (OR 0.11 IC 0.03–0.34). Nulliparity in postmenopausal women and age at menopause were related to an increased risk of SD BC (OR 1.60 IC 1.08–2.36; OR 1.48 IC 1.09–2.00, respectively). Nulliparity in postmenopausal women was associated with a higher risk of HR+ (OR 1.66 IC 1.15–2.40). Age at menopause was related to a greater risk of HR+ (OR 1.60 IC 1.22–2.11) and HER2+ (OR 1.59 IC 1.03–2.45) tumors. Conclusion Reproductive risk factors are associated with SD BC, as are HR+ tumors. Differences in BC-risk factor associations according to detection method may be related to prevailing phenotypes among categories. Supplementary Information The online version contains supplementary material available at 10.1007/s10552-021-01511-4.
Collapse
Affiliation(s)
- Marta Hernández-García
- Cancer and Public Health Area, Foundation for the Promotion of Health and Biomedical Research of Valencia Region(FISABIO), Avda. Catalunya 21, 46020, Valencia, Spain
| | - Ana Molina-Barceló
- Cancer and Public Health Area, Foundation for the Promotion of Health and Biomedical Research of Valencia Region(FISABIO), Avda. Catalunya 21, 46020, Valencia, Spain.
| | - Mercedes Vanaclocha-Espi
- Cancer and Public Health Area, Foundation for the Promotion of Health and Biomedical Research of Valencia Region(FISABIO), Avda. Catalunya 21, 46020, Valencia, Spain
| | - Óscar Zurriaga
- Preventive Medicine and Public Health, Food Sciences, Toxicology and Forensic Medicine Department, University of Valencia, Avda. Vicent Andrés Estellés, s/n, 46100, Burjassot, Valencia, Spain
- Joint Research Unit on Rare Diseases, FISABIO-UVEG, Avda. Catalunya 21, 46020, Valencia, Spain
- Directorate General of Public Health, Avda. Catalunya 21, 46020, Valencia, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - Beatriz Pérez-Gómez
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Department of Epidemiology of Chronic Diseases, National Center of Epidemiology, Carlos III Health Institute (ISCIII), Avda. Monforte de Lemos 5, 28029, Madrid, Spain
| | - Nuria Aragonés
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Epidemiology Section, Public Health Division, Department of Health of Madrid, C/San Martín de Porres, 6, 28035, Madrid, Spain
| | - Pilar Amiano
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Epidemiology of Chronic and Communicable Diseases Group, Biodonostia Health Research Institute, Doctor Begiristain, s/n, 20014, San Sebastián, Spain
- Sub Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, 2013, San Sebastian, Spain
| | - Jone M Altzibar
- Epidemiology of Chronic and Communicable Diseases Group, Biodonostia Health Research Institute, Doctor Begiristain, s/n, 20014, San Sebastián, Spain
- ISGlobal, Barcelona Institute for Global Health, Doctor Aiguader 88, 08003, Barcelona, Spain
| | - Gemma Castaño-Vinyals
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- ISGlobal, Barcelona Institute for Global Health, Doctor Aiguader 88, 08003, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Doctor Aiguader 88, 08003, Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Plaça de la Mercè, 10-12, 08002, Barcelona, Spain
| | - María Sala
- IMIM (Hospital del Mar Medical Research Institute), Doctor Aiguader 88, 08003, Barcelona, Spain
- Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain
| | - María Ederra
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Navarra Public Health Institute, C/ Leyre, 15, 31003, Navarra, Spain
- IdiSNA, Navarra Institute for Health Research, C/Irunlarrea, 3, 31008, Pamplona, Spain
| | - Vicente Martín
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- The Research Group in Gene - Environment and Health Interactions (GIIGAS), Biomedicine Institute (IBIOMED), University of León, Vegazana Campus, s/n, 24071, León, Spain
| | - Inés Gómez-Acebo
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Cantabria University- IDIVAL, C/Cardenal Herrera Oria, s/n, Santander, 39011, Cantabria, Spain
| | - Carmen Vidal
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Cancer Screening Unit, Catalan Institute of Oncology, Duran I Reynals Hospital, Avda. de La Gran Via de L'Hospitalet, 199-203, L'Hospitalet de Llobregat, 08908, Barcelona, Spain
- Early Detection of Cancer Research Group, EPIBELL Program, Bellvitge Biomedical Research Institute, Avda. de La Granvia de L'Hospitalet, 199, L'Hospitalet de Llobregat, 08908, Barcelona, Spain
| | - Adonina Tardón
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Oncology Institute (IUOPA), University of Oviedo, Edificio Santiago Gascón, Campus El Cristo B, 33006, Oviedo, Spain
| | - Rafael Marcos-Gragera
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology. Sant Ponç, Avda de França, 0, 17007, Girona, Spain
- Descriptive Epidemiology, Genetics and Cancer Prevention Group, [Girona Biomedical Research Institute] IDIBGI, C/ del Dr. Castany, s/n, Salt, 17190, Girona, Spain
| | - Marina Pollán
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- National Center of Epidemiology Directorate, Carlos III Health Institute (ISCIII), Avda. Monforte de Lemos 5, 28029, Madrid, Spain
| | - Manolis Kogevinas
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- ISGlobal, Barcelona Institute for Global Health, Doctor Aiguader 88, 08003, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Doctor Aiguader 88, 08003, Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Plaça de la Mercè, 10-12, 08002, Barcelona, Spain
| | - Dolores Salas
- Cancer and Public Health Area, Foundation for the Promotion of Health and Biomedical Research of Valencia Region(FISABIO), Avda. Catalunya 21, 46020, Valencia, Spain
- Directorate General of Public Health, Avda. Catalunya 21, 46020, Valencia, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|